Company Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-13 pm EDT 5-day change 1st Jan Change
43.12 USD -3.41% Intraday chart for Ultragenyx Pharmaceutical Inc. +3.23% -9.83%

Business Summary

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Number of employees: 1,276

Sales per Business

USD in Million2022Weight2023Weight Delta
Crysvita Royalty
42.1 %
22 6.0 % 183 42.1 % +742.02%
Crysvita
17.4 %
43 11.7 % 76 17.4 % +77.37%
Dojolvi
16.3 %
56 15.3 % 71 16.3 % +27.01%
Collaboration and License - Crysvita Collaboration Revenue in Profit-share Territory
16.1 %
215 59.2 % 70 16.1 % -67.58%
Mepsevii
7.0 %
21 5.7 % 30 7.0 % +47.51%
Evkeeza
0.8 %
- - 4 0.8 % -
Collaboration and License - Daiichi Sankyo
0.3 %
8 2.1 % 1 0.3 % -80.76%

Sales per region

USD in Million2022Weight2023Weight Delta
North America
70.7 %
281 77.4 % 307 70.7 % +9.27%
Latin America
17.8 %
45 12.3 % 77 17.8 % +72.98%
Europe
10.9 %
36 10.0 % 48 10.9 % +30.70%
Japan
0.5 %
1 0.3 % 2 0.5 % +91.56%

Managers

Managers TitleAgeSince
Founder 63 10-04-21
Director of Finance/CFO 47 23-10-15
Chief Tech/Sci/R&D Officer - 17-10-31
Chief Tech/Sci/R&D Officer 59 15-04-30
Chief Tech/Sci/R&D Officer 75 17-10-31
Investor Relations Contact - -
Human Resources Officer 60 20-08-31
General Counsel 46 16-06-19
Corporate Officer/Principal 58 11-07-31
Corporate Officer/Principal 54 16-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 61 17-04-05
Founder 63 10-04-21
Chairman 66 15-04-07
Director/Board Member 59 13-12-31
Director/Board Member 64 15-02-19
Director/Board Member 67 21-06-28
Director/Board Member 52 19-01-29
Director/Board Member 51 22-04-18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 83,196,916 79,491,209 ( 95.55 %) 63,575 ( 0.0764 %) 95.55 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.47 %
8,700,007 10.47 % 349 M $
RTW Investments LP
8.525 %
7,087,115 8.525 % 284 M $
BlackRock Advisors LLC
5.808 %
4,828,242 5.808 % 194 M $
Wellington Management Co. LLP
4.929 %
4,097,975 4.929 % 164 M $
Sands Capital Management LLC
4.642 %
3,859,447 4.642 % 155 M $
T. Rowe Price International Ltd.
4.293 %
3,568,873 4.293 % 143 M $
2,851,250 3.430 % 114 M $
2,724,300 3.277 % 109 M $
ClearBridge Investments LLC
2.888 %
2,400,854 2.888 % 96 M $
Oppenheimer Asset Management (Alkeon Subfiler)
2.697 %
2,241,832 2.697 % 90 M $

Company contact information

Ultragenyx Pharmaceutical, Inc.

60 Leveroni Court

94949, Novato

+415 483 8800

http://www.ultragenyx.com
address Ultragenyx Pharmaceutical Inc.(RARE)
  1. Stock Market
  2. Equities
  3. RARE Stock
  4. Company Ultragenyx Pharmaceutical Inc.